| Sign In to gain access to subscriptions and/or personal tools. |
The Demonstration of Immunohistochemical Biomarkers in Methyl Methacrylate-Embedded Plucked Human Hair FolliclesAstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK Correspondence: Address correspondence to Kevin J. Randall, AstraZeneca, 23G5 Mereside, Alderley Park, Macclesfield, Cheshire, UK SK10 4TG; e-mail:kevin.randall{at}astrazeneca.com
Plucked human hair follicles have been proposed as a potential surrogate for tumour tissue for measuring the effect of drugs on pharmacodynamic biomarkers in drug intervention studies. We describe a new technique of embedding plucked hair follicles in the acrylic resin, methyl methacrylate, and the immunohistochemical demonstration of six potential biomarkers (Ki67, EGFR, phospho-p27, phospho-histone H3, phospho-MAPK and phospho-Rb) in de-plasticised sections. The advantages of this technique over those that have been used in support of clinical drug trials, such as skin and tumour biopsies, whole blood and whole hair samples is discussed.
Key Words: Hair Follicle • methyl methacrylate • immunohistochemistry • drug development • biomarker • pharmacodynamic Abbreviations: FFPE, formalin-fixed paraffin embedded • IHC, immunohistochemistry • PD, pharmacodynamic
Early phase clinical trails have traditionally been used to investigate the safety, and dosage levels, of new drugs in volunteers. During these studies there is a regulatory and scientific desire to establish that the drug in question is acting in the expected way in inducing its therapeutic effect. Hence modern drug development frequently involves incorporation of a pharmacodynamic (PD) marker as evidence that the mode of action of the drug on human tissues is via the proposed pathway. Whilst PD effects seen in diseased tissue are likely to relate most closely to clinically relevant outcomes (Baselga, 2003) there is a need, within oncology drug development, to use normal tissue as a surrogate for tumour tissues for two reasons; firstly, healthy volunteers do not have tumours and, secondly, tumour heterogeneity and accessibility in patient volunteers may prove problematic. For a tissue to be a suitable cancer surrogate it has to have similar characteristics in expressing a relatively high rate of proliferation, express the target pathway of the drug, be easily accessible and the sampling be well tolerated. Normal tissue-based oncology biomarker studies have been performed with success using peripheral blood mononuclear cells (Cohen et al., 2003; Peralba et al., 2003), exfoliated buccal squamous cells (van de Vaart et al., 2000; Adjei et al., 2003), punch biopsies of the skin (Albanell et al., 2002; Malik et al., 2003; Vanhoefer et al., 2004) and punch biopsies of buccal mucosa (Camidge et al., 2005a). The sheath around the base of a plucked scalp hair contains proliferating cells (Moll, 1996; Gho et al., 2004), is easily accessible and the plucking is relatively well tolerated. We have previously described a method for performing immunohistochemistry (IHC) on whole plucked human hairs (Camidge et al., 2005b) but this methodology has several drawbacks. In this method the IHC is performed on the intact hair, which is subsequently sectioned to permit morphometric analysis. With this approach only one biomarker can be demonstrated per hair and appropriate controls cannot be performed on the same hair. We determined that multiple hairs needed to be stained for each biomarker to reduce statistical variability. If a panel of biomarkers were to be employed the number of plucked hairs required would soon become impractical and the exercise prohibitively expensive. The IHC staining of intact hairs also had to be done within a limited time after sampling and a significant number were lost or damaged (18%), failed to stain (15%) or showed high and unacceptable levels of background staining (5%). Attempts have been successfully described for sectioning hair shafts (Kempson et al., 2002) but the preparations were not subsequently useful for IHC. Previous attempts in our laboratory to reliably section formalin fixed, paraffin embedded (FFPE), hairs in a longitudinal direction, as is necessary for locating the proliferative areas in the follicle (Ito et al., 2002), have proved extremely difficult mainly due to the difference in hardness between the hair shaft and the wax embedding medium. Resin embedding would appear to provide a solution and the epoxy resin, Araldite, has been used successfully to section hair (Pepper and Lantis, 1977; Rosen and Kerley, 1971) although the inability to subsequently remove the resin from the hair without severe alkaline pretreatment renders the technique unusable for most IHC methodologies (Sato et al., 1995). Many commercially available resins are based on glycol methacrylate (GMA) but reports of attempted IHC staining of tissues embedded in this material are mixed (Beckstead el al., 1986; Archimbaud et al., 1987; Islam et al., 1988; Burgio et al., 1991; Vincic et al., 1990). Chemically polymerised methyl methacrylate (MMA), on the other hand, has been used successfully for tinctorial stains, IHC (Blythe et al., 1997; Hand et al., 1996) and non-isotopic in situ hybridisation (Church et al., 1997). MMA has the advantage over other acrylic and epoxy resins in that sections may be deplasticised by immersion in xylene, similar to the procedure used with wax sections, resulting in the removal of significant stearic hindrance by the embedding medium. We report here a method for the fixation, processing, sectioning and immunohistochemical staining of a number of oncology-relevant antibodies on plucked human hair, using a modification of a method previously described by Blythe et al. (1997), and discuss the possible application of the methodology within clinical trials.
Sampling and Fixation Hairs were plucked from the parietal region of the scalp using blunt-nosed forceps. The hairs were gripped close to the scalp and plucked with a single, sharp action, checked for the presence of sheath, trimmed to approximately 1 cm in length containing the bulb region and dropped into a 1.5 ml microfuge tube (Fisher Scientific, Loughborough, UK) containing 1 ml 10% neutral-buffered formalin. The optimal period of fixation was determined by a time course experiment fixing the hairs for 1, 2, 4, 6, 12 and 24 hours, processing and staining with our most fixation sensitive antibody (anti-phospho-p27, Upstate, Charlottesville, VA) and was found to be 4 hours at room temperature (20°C).
Processing The agarose blocks were trimmed to approximately 6 x 4 x 3 mm and placed in the processing baskets of the Leica EM TP and processed according to the following schedule: PBS, 30 min; PBS, 30 min; 50% Ethanol, 1 hr; 70% Ethanol, 1 hr; 90% Ethanol, 1 hr; 100% Ethanol, 1 hr; 100% Ethanol, 1 hr; 100% Ethanol, 1 hr; Catalysed MMA, 1 hr; Catalysed MMA, 16 hrs. The catalysed MMA infiltration solution consisted of 75 ml methyl methacrylate, 25 ml dibutyl phthalate and 5 g dried benzoyl peroxide (all Sigma-Aldrich). Benzoyl peroxide is potentially explosive in the dry state and is supplied dampened; aliquots are dried overnight in an oven (Memmert GmbH, Schwabach, Germany) at 37°C.
Embedding
Blocks were embedded in 8 mm diameter, flat-ended, embedding capsules (Agar Scientific Ltd), which were filled with the polymerisation solution and then closed. At this point it was possible to orientate the hairs into their desired position for sectioning (longitudinally or transversely). The capsules in a rack were placed on a tray within a desiccator (Fisher Scientific, Loughborough, UK). To dissipate the heat generated be the exothermic polymerisation of the resin, water was added to the tray at a level half way up the capsules. The desiccator was closed and the air flushed out with oxygen-free nitrogen. The polymerisation of the resin takes approximately 2
Sectioning
Immunohistochemistry
Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide in TBST for 10 minutes. Slides were then washed and incubated for 20 minutes with 5% normal goat serum in TBST. Excess blocking serum was blown off and the slides were incubated with the primary antibodies for 60 minutes. Following washing the slides were incubated for 30 minutes in either rabbit- or mouse-specific EnVision® + System–HRP (Dako UK Ltd, Ely, UK), depending on the source of the primary antibody, and visualised by incubation in diaminobenzidine (DAB), from the EnVision® + kits, for 10 minutes. The slides were counterstained for 1 minute using Carazzi’s haematoxylin (Clin-Tech, Guildford, UK). Staining was negatively controlled by substituting mouse isotype immunoglobulin (Ig) or rabbit Ig fraction, diluted to the same concentration, for the primary antibodies. Sections of SW620 human colorectal xenograft tumours, grown in Nude mice, which had previously been successfully stained with these antibodies, were used as positive controls. Following staining between 4 and 10 hair sections for each antibody were assessed microscopically by eye for the intensity and the approximate percentage of cells stained was estimated.
Using this method up to 50 section of 4 µm thickness could be obtained and successful immunohistochemical staining was achieved with all six antibodies (Figure 1).
Ki67 (Fig 1a) The proliferation marker showed strong staining of approximately 10% of the nuclei around the periphery of the hair sheath, an area known as the outer root sheath (ORS), which is considered to derive from epithelial stem cells and be actively proliferative (Krause et al., 2006).
EGFR (Fig 1b)
Phospho-p27 (Fig 1c)
Phospho-Histone H3 (Fig 1d)
Phospho-p44/42MAPK (Fig 1e)
Phospho (S249/T252)-Rb (Fig 1f)
The importance of being able to monitor the effects of therapeutic drugs on cancer cannot be over stated (Severino et al., 2006; Colburn, 2003; Lee et al., 2007). In the field of oncology clinical trials, this has most commonly involved the sampling of biopsy material from either the cancer itself, or by taking blood, and analysing for changes in the function of the putative target (Nishio et al., 2005; Cummings et al., 2004; Elyin et al., 2004). Whilst a shift in the expression of biomarkers in the tumour itself remains the ideal goal, and would be more indicative of drug activity in the disease target (Baselga, 2003), obtaining tumour material is not always possible, practicable or tolerable. Healthy volunteers in phase 1 clinical trials will, by definition, have no tumour to biopsy making the use of a surrogate unavoidable. In patient volunteers it may be difficult to obtain permission for multiple biopsies pre- and post-dose. Additionally, tumour heterogeneity may pose problems when trying to compare paired biopsies. Also, these techniques are generally invasive to varying degrees, involve a certain degree of risk to the subjects, and are variably tolerable by those undergoing the procedure (Duran et al., 2006; Albanell et al., 2002; Soo et al., 2006; Ma and Chan, 2006; Kindler et al., 2004; Stathopoulos et al., 2005). Although peripheral blood cells are readily accessible, their low intrinsic proliferation rates make them a poor marker for the effects of anti-proliferative, anti-cancer, agents unless ex vivo induction of cell proliferation, using mitogenic agents such as phytohaemagglutinin, tetanus toxoid, or interleukin-2 (Rosato et al., 2001; Ingham et al., 1991) are employed. Plucked human hair offers a minimally-invasive, easily sampled and well-tolerated source of cells for the investigation of the pharmacodynamic (PD) effects of specific anti-proliferative drugs on human tissue. We have shown that a number of important biomarkers of cell cycling, in its broadest sense, may be demonstrated immunohistochemically on plucked and sectioned hair follicles using this technique and the current methodology has a number of advantages over methods previously described (Camidge et al., 2005b). Immunohistochemistry, as with any assay, needs to have the appropriate controls, both positive and negative (Leong and Leong, 2006; Chan et al., 2000; Maxwell and McCluggage, 2000). This was difficult to achieve with the whole hair methodology as each hair follicle could only be stained once. The current method allows multiple serial sections from the same hair to be used for both the novel immunohistochemical marker and the appropriate controls. The ability to derive up to 50 sections from each plucked hair follicle also enables multiple assays to be performed on a single hair, reducing the overall number of hairs required and leading to a reduction in both the experimental costs and patient discomfort. An additional advantage is the ability, once the samples have been processed and embedded, to store the blocks for additional investigations at a later date. This is not possible with the whole hair method (Camidge et al., 2005b) where the whole sample has to be used for each stain employed. The new methodology subsequently permits considerably greater flexibility in workload scheduling by avoiding the necessity for multiple sampling from each volunteer at each time point in the study. The great advantage of methyl methacrylate in immunohistochemistry over other commonly used resins is the ability to remove the resin by immersion in xylene (Britten et al., 1993; Howat et al., 2005), the consequence being that IHC methods developed on FFPE tissues may be transferred to MMA embedded tissues with little or no modification. This is advantageous to the investigator, saving time in method development and strengthening confidence in the assay. Furthermore having sections equivalent in most respects to de-waxed FFPE sections enables the application of haematoxylin as a nuclear counterstain, which helps place the IHC into context and as a means of normalising any subsequent image analysis. In conclusion, the methodology described has the potential to make hair sampling a valuable and versatile tool for monitoring the effects of anti-cancer drugs on cell proliferation, and on the upstream signalling molecules that control cell proliferation. Obtaining hair samples is minimally invasive and sectioning of the hair allows a large number of samples to be obtained for subsequent immunohistochemistry. It should be a valuable additional tool to the range of techniques currently being applied in early phase clinical trials of potential drugs.
Adjei, AA, Mauer, A, Bruzek, L, Marks, RS, Hillman, S, Geyer, S, Hanson, LJ, Wright, JJ, Erlichman, C, Kaufman, SH, & Vokes, EE. (2003). Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small cell lung cancer. J Clin Oncol, 21, 1760-1766 Albanell, J, Rojo, F, Averbuch, S, Feyereislova, A, Mascaro, JM, Herbst, R, LoRusso, P, Rischin, D, Sauleda, S, Gee, J, Nicholson, RI, & Baselga, J. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular cosequences of receptor inhibition. J Clin Oncol, 20, 110-124 Archimbaud, E, Islam, A, & Preisler, HD. (1987). Immunoperoxidase detection of myeloid antigens in glycol methacrylate embedded human bone marrow. Histochem Cytochem, 35, 595-599[Abstract] Baselga, J. (2003). Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res, 9, 2389-2390 Beckstead, JH, Stenberg, PE, McEver, RP, Shuman, MA, & Bainton, DF. (1986). Immunohistochemical localization of membrane and a-granule proteins in human megakaryocytes: application to plastic-embedded bone marrow biopsy specimens. Blood, 67, 285-293 Blythe, D, Hand, NM, Jackson, P, Barrans, SL, Bradbury, RD, & Jack, AS. (1997). Use of methyl methacrylate resin for embedding bone marrow trephine biopsy specimens. J Clin Pathol, 50, 45-49 Britten, KM, Howarth, PH, & Roche, WR. (1993). Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem, 68, 271-280[Web of Science][Medline] [Order article via Infotrieve] Burgio, VL, & Pignoloni, CD. (1991). Immunohistology of bone marrow: a modified method of glycol methacrylate embedding. Histopathology, 18, 37-43[Web of Science][Medline] [Order article via Infotrieve] Camidge, DR, Pemberton, MN, Growcott, JW, Johnstone, D, Laud, PJ, Foster, JR, Randall, KJ, & Hughes, AM. (2005a). Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development. Br J Cancer, 93, 208-215[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Camidge, DR, Randall, KJ, Foster, JR, Sadler, CJ, Wright, JA, Soames, AR, Laud, PJ, Smith, PD, & Hughes, AM. (2005b). Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies. Br J Cancer, 92, 1837-1841[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Chan, JK, Wong, CS, Ku, WT, & Kwan, MY. (2000). Reflections on the use of controls in immunohistochemistry and proposal for application of a multitissue spring-roll control block. Ann Diagn Pathol, 4, 329-336[CrossRef][Medline] [Order article via Infotrieve] Church, RJ, Hand, NM, Rex, M, & Scotting, PJ. (1997). Non-isotopic in situ hybridization to detect chick Sox gene mRNA in plastic-embedded tissue. Histochem J, 29, 625-629[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Cohen, SJ, Ho, L, Ranganathan, S, Abbruzzese, JL, Alpaugh, RK, Beard, M, Lewis, NL, McLaughlin, S, Rogatko, A, Perez-Ruixo, JJ, Thistle, AM, Verhaeghe, T, Wang, H, Weiner, LM, Wright, JJ, Hudes, GR, & Meropol, NJ. (2003). Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol, 21, 1301-1306 Colburn, WA. (2003). Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol, 43, 329-341 Cummings, J, Ward, TH, Ranson, M, & Dive, C. (2004). Apoptosis pathway-targeted drugs–from the bench to the clinic. Biochim Biophys Acta, 1705, 53-66[Medline] [Order article via Infotrieve] Duran, I, Kortmansky, J, Singh, D, Hirte, H, Kocha, W, Goss, G, Le, L, Oza, A, Nicklee, T, Ho, J, Birle, D, Pond, GR, Arboine, D, Dancey, J, Aviel-Ronen, S, Tsao, MS, Hedley, D, & Siu, LL. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer, 95, 1148-1154[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Gho, CG, Braun, JE, Tilli, CM, Neumann, HA, & Ramaekers, FC. (2004). Human follicular stem cells: their presence in plucked hair and follicular cell culture. Br J Dermatol, 150, 860-868[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Hand, NM, Blythe, D, & Jackson, P. (1996). Antigen unmasking using microwave heating on formalin fixed tissue embedded in methyl methacrylate. J Cell Pathol, 1, 31-37[Medline] [Order article via Infotrieve] Heymach, JV, Desai, J, Manola, J, Davis, DW, McConkey, DJ, Harmon, D, Ryan, DP, Goss, G, Quigley, T, Van den Abbeele, AD, Silverman, SG, Connors, S, Folkman, J, Fletcher, CD, & Demetri, GD. (2004). Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res, 10, 5732-5740 Howat, WJ, Warford, A, Mitchell, JN, Clarke, KF, Conquer, JS, & McCafferty, J. (2005). Resin tissue microarrays: a universal format for immunohistochemistry. J Histochem Cytochem, 53, 1189-1197 Ilyin, SE, Belkowski, SM, & Plata-Salamán, CR. (2004). Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol, 22, 411-416[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Ingham, E, Turnbull, L, & Kearney, JN. (1991). The effects of minocycline and tetracycline on the mitotic response of human peripheral blood-lymphocytes. J Antimicrob Chemother, 27, 607-617 Islam, A, Archimbaud, E, Henderson, ES, & Han, T. (1988). Glycol methacrylate (GMA) embedding for light microscopy. II. Immunohistochemical analysis of semithin sections of undecalcified marrow cores. J Clin Pathol, 41, 892-896 Ito, M, Kizawa, K, Toyoda, M, & Morohashi, M. (2002). Label-retaining Cells in the Bulge Region are Directed to Cell Death after Plucking, Followed by Healing from the Surviving Hair Germ. J Invest Dermatol, 119, 1310-1316[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Kempson, IM, Skinner, WM, & Kirkbride, PK. (2002). A method for the longitudinal sectioning of single hair samples. J Forensic Sci, 47, 889-892[Web of Science][Medline] [Order article via Infotrieve] Kindler, T, Breitenbuecher, F, Marx, A, Beck, J, Hess, G, Weinkauf, B, Duyster, J, Peschel, C, Kirkpatrick, CJ, Theobald, M, Gschaidmeier, H, Huber, C, & Fischer, T. (2004). Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood, 103, 3644-54 Krause, K, & Foitzik, K. (2006). Biology of the hair follicle: the basics. Semin Cutan Med Surg, 25, 2-10[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Lee, JW, Figeys, D, & Vasilescu, J. (2007). Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res, 96, 269-298[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Leong, AS, & Leong, TY. (2006). Newer developments in immunohistology. J Clin Pathol, 59, 1117-1126 Ma, BBY, & Chan, ATC. (2006). Transcriptional profiling of tumor biopsies in oncology trialsa ‘window’ of opportunity for evaluating new drugs in nasopharyngeal cancer? Ann Oncol, 17, 1611-1613 Malik, SN, Siu, LL, Rowinsky, EK, de Graffenreid, L, Hammond, LA, Rizzo, J, Bacus, S, Brattain, MG, Kreisberg, JI, & Hidalgo, M. (2003). Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res, 9, 2478-2486 Maxwell, P, & McCluggage, WG. (2000). Audit and internal quality control in immunohistochemistry. J Clin Pathol, 53, 929-932 Moll, I. (1996). Differential epithelial outgrowth of plucked and microdissected human hair follicles in explant culture. Arch Dermatol Res, 288, 604-610[Web of Science][Medline] [Order article via Infotrieve] Nishio, K, Arao, T, Shimoyama, T, Fujiwara, Y, Tamura, T, & Saijo, N. (2005). Translational studies for target-based drugs. Cancer Chemother Pharmacol, 1(56, Suppl), 90-93 Pepper, MC, & Lantis, SD. (1977). A new technique for cross sectioning free hairs. J Invest Dermatol, 68, 111-112[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Peralba, JM, de Graffenreid, L, Friedrichs, W, Fulcher, L, Grunwald, V, Weiss, G, & Hidalgo, M. (2003). Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res, 9, 2887-2892 Rosato, MT, Jabbour, AJ, Ponce, RA, Kavanagh, TJ, Takaro, TK, Hill, JP, Poot, M, Rabinovitch, PS, & Faustman, EM. (2001). Simultaneous analysis of surface marker expression and cell cycle progression in human peripheral blood mononuclear cells. J Immunol Methods, 256, 35-46[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Rosen, SI, & Kerley, ER. (1971). An epoxy method of embedding hair for histologic sectioning. J Forensic Sci, 16, 236-240[Medline] [Order article via Infotrieve] Sato, Y, Ito, T, Nozawa, A, & Kanisawa, M. (1995). Bromodeoxyuridine and iododeoxyuridine double immunostaining for epoxy resin sections. Biotech Histochem, 70, 169-174[Web of Science][Medline] [Order article via Infotrieve] Severino, ME, Dubose, RF, & Patterson, SD. (2006). A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development. IDrugs, 9, 849-853[Web of Science][Medline] [Order article via Infotrieve] Soo, RA, Wu, J, Aggarwal, A, Tao, Q, Hsieh, W, Putti, T, Tan, KB, Soon, WL, Lai, YF, Mow, B, Hsu, S, Loh, KS, Tan, L, Tan, P, & Goh, BC. (2006). Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Annals Oncol, 17, 1625-1630 Stathopoulos, GP, Rigatos, SK, Stathopoulos, JG, Xynotroulas, JP, & Dimou, E. (2005). Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Am J Clin Oncol, 28, 565-569[CrossRef][Web of Science][Medline] [Order article via Infotrieve] van de Vaart, PJM, Belderbos, J, de Jong, D, Sneeuw, KCA, Majoor, D, Bartelink, H, & Begg, AC. (2000). DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer, 89, 160-166[CrossRef][Web of Science][Medline] [Order article via Infotrieve] Vanhoefer, U, Tewes, M, Rojo, F, Dirsch, O, Schleucher, N, Rosen, O, Tillner, J, Kovar, A, Braun, AH, Trarbach, T, Seeber, S, Harstrick, A, & Baselga, J. (2004). Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumours that express the epidermal growth factor receptor. J Clin Oncol, 22, 175-184 Vincic, L, Colley, EC, Beltrano, A, & Riddell, RH. (1990). Plastic versus paraffin embedding for histopathology and immunocytochemistry [letter]. Am J Surg Pathol, 14, 500-501[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
Toxicologic Pathology, Vol. 35, No. 7,
952-957 (2007)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
Top
Abstract
Introduction
hours after which the resin blocks were removed from their capsules and stored at room temperature before sectioning. 